enGene (NASDAQ:ENGN) Coverage Initiated at JMP Securities

JMP Securities started coverage on shares of enGene (NASDAQ:ENGN - Free Report) in a research note published on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $18.00 target price on the stock.

A number of other analysts have also recently weighed in on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reaffirmed an "overweight" rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $31.43.

enGene Stock Up 0.4 %

ENGN traded up $0.03 on Monday, hitting $7.66. 27,585 shares of the company were exchanged, compared to its average volume of 111,495. The business's fifty day moving average is $7.66 and its 200 day moving average is $8.71. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. Equities analysts forecast that enGene will post -1.54 EPS for the current fiscal year.

Insider Activity at enGene

In related news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $5.70 per share, with a total value of $57,000.00. Following the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of the firm's stock in a transaction on Monday, October 7th. The shares were purchased at an average cost of $6.55 per share, for a total transaction of $77,578.20. Following the completion of the purchase, the insider now directly owns 2,469,833 shares of the company's stock, valued at approximately $16,177,406.15. The trade was a 0.48 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 420,965 shares of company stock worth $2,651,103. 13.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Altitude Crest Partners Inc. bought a new position in enGene during the first quarter worth about $2,039,000. Janus Henderson Group PLC acquired a new stake in shares of enGene in the 1st quarter valued at approximately $17,095,000. SR One Capital Management LP acquired a new position in enGene during the second quarter worth approximately $4,715,000. Logos Global Management LP raised its holdings in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. Finally, Wolverine Asset Management LLC acquired a new stake in enGene in the 3rd quarter worth about $37,000. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.